DLL3 and cancer: For tumor‐associated EVs (tEV), we tested the capture efficiency of four cancer cell membrane‐specific antibodies: EGFR, EpCAM, ROR1, and DLL3.[52, 53, 54, 55] Although EGFR is highly upregulated in many cancer types, it was inefficient for sorting SCLC EVs and quantifying DLL3 protein (Figure S3B, Supporting Information).